Commentary

Article

State of the Science Summit - Hematologic Malignancies: Chaired by Jennifer Amengual, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Jennifer Amengual, MD

State of the Science Summit - Hematologic Malignancies: Chaired by Jennifer Amengual, MD

Speakers

  • Joseph G. Jurcic, MD | Columbia University Herbert Irving Comprehensive Cancer Center
  • Sunil Iyer, MD | Columbia University Herbert Irving Comprehensive Cancer Center
  • Andrew H Lipsky, MD | Columbia University Herbert Irving Comprehensive Cancer Center
  • Hua-Jay J Cherng, MD | Columbia University Herbert Irving Comprehensive Cancer Center

Topics

  • Treatment of patients with myelofibrosis
  • Emerging treatment standards for MDS
  • Use of BTK inhibitors in MCL and CLL
  • Bispecific antibodies in DLBCL
  • Top 5 abstracts from ASH 2023

Interested in attending a live or virtual event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science SummitsClick here to listen to our latest episodes!

Related Videos
Justin M. Watts, MD
Mazyar Shadman, MD, MPH
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Hannah Choe, MD, an expert on GVHD
Hannah Choe, MD, an expert on GVHD
Grzegorz S. Nowakowski, MD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients With Relapsed or Refractory CLL/SLL: Results From the Phase 1 BGB-16673-101 Study